Huang-Lian-Jie-Du-Decoction modulates glucagon-like peptide-1 secretion in diabetic rats

被引:49
作者
Yu, Yun-Li [1 ]
Lu, Shou-Si [1 ]
Yu, Sen [1 ]
Liu, Yu-Chun [1 ]
Wang, Ping [1 ]
Xie, Lin [1 ]
Wang, Guang-Ji [1 ]
Liu, Xiao-Dong [1 ]
机构
[1] China Pharmaceut Univ, Key Lab Drug Metab & Pharmacokinet, Nanjing 210009, Peoples R China
基金
美国国家科学基金会;
关键词
Huang-Lian-Jie-Du-Decoction; Diabetes; Glucagon-like peptide (GLP)-1 (7-36) amide; Proglucagon; L cell; Beta cell; BODY-WEIGHT; BERBERINE; AMIDE; THERAPY; GLP-1;
D O I
10.1016/j.jep.2009.05.027
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Aim of the study: Huang-Lian-Jie-Du-Decoction (HLJDD), a well-known Chinese herbal formula, has been used for diabetic treatment. The purpose of the study was to investigate whether HLJDD affected glucagon-like peptide (GLP)-1 (7-36) amide level in diabetic rats. Materials and methods: Streptozotocin (STZ)-induced diabetic rats were treated with HLJDD at low dose (2 g/kg/day)or high dose (4 g/kg/day). After 5-week treatment, GLP-1 (7-36) amide level and insulin level in portal vein and tissues stimulated by oral glucose load were measured by ELISA kits. The proglucagon gene expression in intestinal tracts and the proliferation of intestinal L cell and pancreatic beta cell were measured using RT-PCR and immunohistochemistry techniques, respectively. Results: It was found that 5-week HLJDD treatment attenuated alteration of glucose level and insulin level in plasma and tissues of diabetic rats induced by STZ, accompanied by improvement of diabetic syndrome. 5-week HLJDD treatment increased GLP-1 (7-36) amide level in portal vein plasma and distal ileum. Further studies showed that 5-week HLJDD treatment increased the mRNA level of proglucagon gene in distal ileum, promoted pancreatic beta cell and intestinal L cell proliferation in a dose-dependent manner. Conclusion: All the results indicated that HLJDD exerted its anti-diabetic effects partly via modulating GLP-1 (7-36) amide level. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:444 / 449
页数:6
相关论文
共 20 条
[1]  
Amer Diabet Assoc, 2005, DIABETES CARE, V28, pS37
[2]  
[Anonymous], 2000, ZHONGHUA ZHONGYI YAO
[3]   GLP-1 based therapy for type 2 diabetes [J].
Arulmozhi, DK ;
Portha, B .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2006, 28 (1-2) :96-108
[4]   Glucagon-like peptide-1 and glucagon-like peptide-2 [J].
Baggio, LL ;
Drucker, DJ .
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 18 (04) :531-554
[5]   Involvement of endogenous glucagon-like peptide-1(7-36) amide on glycaemia-lowering effect of oligofructose in streptozotocin-treated rats [J].
Cani, PD ;
Daubioul, CA ;
Reusens, B ;
Remacle, C ;
Catillon, G ;
Delzenne, NM .
JOURNAL OF ENDOCRINOLOGY, 2005, 185 (03) :457-465
[6]   Inulin-type fructans modulate gastrointestinal peptides involved in appetite regulation (glucagon-like peptide-1 and ghrelin) in rats [J].
Cani, PD ;
Dewever, C ;
Delzenne, NM .
BRITISH JOURNAL OF NUTRITION, 2004, 92 (03) :521-526
[7]  
Chen Guang, 2007, Zhong Xi Yi Jie He Xue Bao, V5, P412, DOI 10.3736/jcim20070410
[8]   GLP-1 and type 2 diabetes: physiology and new clinical advances [J].
Combettes, Murielle M. J. .
CURRENT OPINION IN PHARMACOLOGY, 2006, 6 (06) :598-605
[9]  
[邓远雄 DENG Yuanxiong], 2008, [药物分析杂志, Chinese Journal of Pharmaceutical Analysis], V28, P182
[10]   Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins [J].
Kong, WJ ;
Wei, J ;
Abidi, P ;
Lin, MH ;
Inaba, S ;
Li, C ;
Wang, YL ;
Wang, ZZ ;
Si, SY ;
Pan, HN ;
Wang, SK ;
Wu, JD ;
Wang, Y ;
Li, ZR ;
Liu, JW ;
Jiang, JD .
NATURE MEDICINE, 2004, 10 (12) :1344-1351